Skip to main content
A

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 1% confidence The document is a corporate “进展公告” (progress announcement) detailing the status of a “quality return dual enhancement” action plan, including business performance metrics, R&D progress, governance improvements, share repurchase updates and a proposed dividend distribution (pending shareholder approval). It is not a formal annual report or audit report, nor a standalone earnings release, investor presentation, or AGM/EGM voting results announcement. It contains substantive disclosure but does not fit any of the more specific categories (e.g., pure dividend notice, pure share repurchase, or management discussion accompanying a quarterly report). Therefore, it falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-15 Chinese
关于回购注销2023年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 1% confidence The document is a formal announcement detailing the company’s repurchase and cancellation of its own restricted shares under its 2023 equity incentive plan, including number of shares, price, approvals by board and committees, capital change effects, and legal opinions. This fits the category of a transaction in the company’s own shares (share buyback/repurchase) rather than a financial report, management change, or dividend notice.
2026-04-15 Chinese
关于2025年度利润分配方案的公告
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement by the company regarding its 2025 profit distribution plan, detailing the cash dividend per share, total amount to be paid, conditions, and compliance with relevant regulations. It does not present full financial statements or management discussion but specifically communicates the dividend scheme to shareholders. This matches the “Notice of Dividend Amount” category.
2026-04-15 Chinese
董事会关于独立董事独立性评估的专项意见
Governance Information Classification · 1% confidence The document is a board-issued special opinion assessing the independence of the company’s independent directors, referencing governance rules and internal board requirements. It does not announce any change of personnel (so not MANG), nor is it a financial report. It details corporate governance practices and the application of internal/exchange rules on director independence, fitting the Governance Information category (CGR).
2026-04-15 Chinese
第四届董事会第十一次会议决议公告
Regulatory Filings Classification · 1% confidence The document is a formal announcement of the resolutions passed at the company’s fourth board of directors’ eleventh meeting, covering approvals of management reports, annual report proposals, dividend distributions, internal control evaluations, credit applications, share repurchases, amendments to compensation policies, and the scheduling of the shareholders’ meeting. It is neither the annual report itself nor a management discussion, nor does it announce changes to board composition. Instead, it is a routine regulatory disclosure of board meeting resolutions, which does not fall under any more specific category, so it is classified as a general regulatory filing (RNS).
2026-04-15 Chinese
审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 1% confidence The document is a standalone report by the company’s Audit Committee detailing its oversight of the external auditor (立信会计师事务所) for the 2025 financial year, covering auditor qualifications, independence, engagement approval, scope of work, communication, and fees. It is audit‐related information separate from a full annual report, matching the “Audit Report / Information” category.
2026-04-15 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.